The University of Queensland

The Provost, Fellows, Foundation Scholars, and the Other Members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin

The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth, Near Dublin

Avril Robertson

Matthew Cooper

Luke O'Neill

Rebecca Coll

Kate Schroder

David John Miller

Angus Murray MacLeod

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: wherein Q is selected from O, S and Se; J is S or Se; Wand W, when present, are independently selected from N and C; Rand Rare independently selected from the group consisting of hydrogen, C-Calkyl, C-Calkenyl, C-Calkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of Wand Wis present and is a nitrogen atom and when Ror Rare cyclic then the respective Wor Wmay form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.

Sulfonylureas and related compounds and use of same

The present invention relates to compounds of formula (I): wherein Q is O or S; Ris a cyclic group substituted with at least one group X, wherein Rmay optionally be further substituted; X is any group comprising a carbonyl group; and Ris a cyclic group substituted at the &#x3b1;-position, wherein Rmay optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRPinhibition and the stimulation of insulin secretion.

Compounds and uses

The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

Growing community of inventors

Kenmore, Australia

Avril Robertson